



FFW

PATENT CASE: JB06017US01

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

-----X		
In re Application of: <b>TAREMI et al.</b>	:	Examiner: To Be Assigned
	:	
For Patent: <b>SOLUBLE, STABLE FORM OF</b>	:	Date: August 26, 2004
<b>HDM2, CRYSTALLINE FORMS</b>	:	
<b>THEREOF AND METHODS OF USE</b>	:	
<b>THEREOF</b>	:	
	:	Group Art Unit: To Be Assigned
Serial No.: 10/822,254	:	
	:	
Filed: 04/09/2004	:	
-----X		

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450  
Mail Stop: Amendment

Sir:

(a) Pursuant to Rule 56, it is requested that the documents listed on the accompanying PTO-1449 Form be considered and made of record in the above-identified patent application. Copy(ies) of these references ☒ are attached ☐ were filed in related application U.S. Serial No(s) \_\_\_\_\_ filed \_\_\_\_\_, respectively.

(b) ☒ No fee is believed due because:

- ☐ This Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- ☐ This Information Disclosure Statement is being concurrently filed with the above-identified application.
- ☐ This Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
- ☒ This Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

(c) ☐ This Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable

inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; or

- ☐ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
- (d) ☐ This Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and
- ☐ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 19-0365, Patent Case No. JB06017US01. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,

SCHERING-PLOUGH CORPORATION

Dated: August 26, 2004

By:

Karen E. Brown  
Karen E. Brown

SCHERING-PLOUGH CORPORATION  
Patent Department, K-6-1, 1990  
2000 Galloping Hill Road  
Kenilworth, NJ 07033-0530  
Facsimile No.: (908) 298-5388

Name: **Karen E. Brown**  
Reg. No.: **43,866**  
**Attorney of Record**  
Telephone No.: (908) 298-2902

I hereby certify that this correspondence is being deposited  
With the U.S. Postal Service as First Class Mail in an envelope  
addressed to Commissioner for Patents, Mail Stop: Amendment,  
P.O. Box 1450, Alexandria, VA 22313-1450 on August 26, 2004.

Karen E. Brown  
Karen E. Brown

August 26, 2004  
Date of Signature



Sheet 1 of 1

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: JB06017US01	APPLICATION NO.: 10/822,254
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT: Shahriar Shane Taremi, et al.	
		FILING DATE: 04/09/2004	GROUP: To Be Assigned

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	2002/0045192 A1	04/18/02	Kriwacki, et al.	435	7.1	

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

AB	Böttger, Angelika, <i>et al.</i> , "Molecular Characterization of the hdm2-p53 Interaction," <i>J. Mol. Biol.</i> <b>269</b> :744-756 (1997)
AC	Chéne, Patrick, <i>et al.</i> , "A Small Synthetic Peptide, which Inhibits the p53-hdm2 Interaction, Stimulates the p53 Pathway in Tumour Cell Lines," <i>J. Mol. Biol.</i> <b>299</b> :245-253 (2000)
AD	Chéne, Patrick, "Inhibiting the p53-MDM2 Interaction: An Important Target for Cancer Therapy," <i>Nature. Reviews Cancer</i> <b>3</b> :102-109 (February 2003)
AE	Kussie, Paul H., <i>et al.</i> , "Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain," <i>Science</i> <b>274</b> :948-53 (November 8, 1996)

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.